CG Oncology’s stock up as gene therapy gains second win in NMIBC
CG Oncology’s adenovirus-based oncolytic viral immunotherapy has shown significant improvements in a Phase III non-muscle invasive bladder cancer (NMIBC) trial.…
CG Oncology’s adenovirus-based oncolytic viral immunotherapy has shown significant improvements in a Phase III non-muscle invasive bladder cancer (NMIBC) trial.…